Introduction
Since organ transplantation medicine has developed and succeeded recently, CMV infection is now being taken seriounly as a complication of post-transplantation status1).
The problem is that it has been difficult to diagnose CMV infection accurately and immediately, with the result that treatment for possible CMV infection or CMV disease has been started even when labora- It has been said that all types of immunocompromised hosts, such as infants, the elderly , patients with advanced cancer, and patients undergoing treatment with immunosuppressants, etc., are susceptible to CMV infection or CMV disease1). We wondered if this was true, but no standardized objective method was available to investigate this question properly . When we were given an opportunity to use the above-mentioned PCR laboratory test, the first standardized objective test for CMV infection , we used it to identify the conditions that facilitate CMV infection in the immunocompromised patients . 
Results

Cytomegalovirus detection in the plasma of healthy volunteers
It has been assumed that if CMV DNA is detected in a patient's plasma, the patient can be diagnosed as having CMV infection. In other words, CMV is never detected in the plasma ofa healthy person. Although this would seems to be true, no evidence has ever been published to corroborate it. We therefore tried to confirm the validity of this conclusion by using the AMPLICORTM CMV test. We investigated whether it would be possible to detect CMV in the plasma of healthy volunteers.Two different subject groups were established: [1] healthy volunteers who had never been infected by CMV (IgG titer for CMV<4) and [2] healthy volunteers who had been already infected by CMV (IgG titer for CMV (Fig.  1) . Neither of the two groups included any persons who exhibited CMV viremia intheir plasma (Fig, 1) . These findings suggest that CMV cannot be detected in the plasma of healthy humans. Thus, if CMV DNA in detected in a patient's plasma, the patient can be diagnosed as having CMV infection.
Cytomegalovirus detection in the plasma of immunocompromised patients We attempted to identify the underlying conditions that facilitate CMV infection (Fig. 2) . Only one patient in the benign disease category had CMV vimemia; but all of the others were negative for CMV infection. None of the patients in the hematopoietic malignancy category had CMV infection; the patients in this group had never undergone bone marrow transplantation.
Twenty-eight patients in the post-bone-marrow transplantation category were positive for CMV viremia, and 19patients were positive in the post-renal transplantation category. The non-parametric Kruskal-Wallis test was applied to these results (Fig. 2) , and a statistically significant difference in positivity for CMV viremia was found among these four categories (p<0.0001). Basea on these findings, we conclude that CMVinfection tends to occur in post-transplantation status and that it dose not tend to occur in patients with hematopoietic malignancy if they have not undergone transplantation. 
